ELIZABETH RAUSCHENBERG: Open Payments
NPI 1548770985 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,978 in 49 payments from 24 companies in 2025. Trend: 2023 $653 · 2024 $1,880 · 2025 $1,978
Long term medical supply or device loan: $1,000Food & beverage: $878Education: $100
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 17 | $1,124 |
| Daiichi Sankyo Inc. | 3 | $155 |
| ABBVIE INC. | 3 | $98 |
| Merck Sharp & Dohme LLC | 3 | $85 |
| Janssen Biotech, Inc. | 3 | $82 |
| AstraZeneca Pharmaceuticals LP | 2 | $50 |
| PharmaEssentia USA Corporation | 1 | $32 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $28 |
| Syndax Pharmaceuticals, Inc. | 1 | $28 |
| BeiGene USA, Inc. | 1 | $27 |
Products named: KISQALI, Enhertu, KEYTRUDA, ELAHERE, SCEMBLIX, TECVAYLI, BESREMI, EPKINLY.
Industry payments across DC — which companies pay providers there.
